Hannah Barman

HER2‐Ultralow: Prevalence, Characteristics, and Treatment Choices Among Advanced Breast Cancer Patients With Tumors Initially Scored as IHC 0

Anushree R. Iyengar, Erinn P. Downs, Sandhya Mehta, Nivedita Rangarajan et autres

Historically, HER2 status in invasive breast cancer has been categorized as HER2-positive (IHC 3+, IHC 2+/ISH+) or HER2-negative (IHC 0, IHC 1+, IHC 2+/ISH-). Patients meeting IHC 0 with membrane staining (HER2-ultralow) criteria may benefit from HER2-targeted therapies such as trastuzumab deruxtecan. …

us, jp (code pays fourni par la source)

Challenges in Evaluating Clinical Remission in Severe Asthma: Insights from the Mayo Clinic

Kaiser G. Lim, Arijita Deb, Thomas C. Corbridge, Lydia Lee et autres

INTRODUCTION: Clinical remission (CR) is an ambitious and achievable treatment goal for many patients with severe asthma. This study evaluated real-life care of patients in the U.S. using CR criteria defined by the American Thoracic Society; American College of Allergy, Asthma, and …

us (code pays fourni par la source)

Assessing Real-world Natural History of Indolent Systemic Mastocytosis: Retrospective Matched Cohort Study from Mayo Clinic Electronic Health Records

Thanai Pongdee, Dakota Powell, Taylor Mai Weis, Robyn Marie Scherber et autres

USING MACHINE LEARNING TO ESTIMATE THE PREVALENCE OF PULMONARY HYPERTENSION AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Hilary M. DuBrock, Kathryn Del Valle, Tyler D. Wagner, Hannah Barman et autres

LEVERAGING ARTIFICIAL INTELLIGENCE TO FACILITATE PATIENT SCREENING: REVEALING THE INFLUENTIAL CLINICAL FEATURES BEHIND MACHINE LEARNING MODELS FOR PH-COPD

Hilary M. DuBrock, Kathryn Del Valle, Hannah Barman, Tyler D. Wagner et autres

Real-world assessment of clinical remission in asthma with biologics

Peter Hugo Howarth, Kaiser G. Lim, Tom Corbridge, Lydia Lee et autres

Background: Clinical Remission (CR) in severe asthma patients treated with biologics, encompassing a broad range of criteria as defined by ATS/ACAAI/AAAAI, provides an ambitious treatment goal but its real-world application remains poorly understood. Aims and Objectives: This study evaluates the extent to …

de, us (code pays fourni par la source)

Physician- and model-reported factors to identify pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD)

Hilary M. DuBrock, Kathryn Del Valle, Hannah Barman, Katherine Carlson et autres

Background: Due to frequent misdiagnosis, invasive diagnostic tests, and lack of approved therapies, screening for PH among patients with COPD is not routinely performed. Machine learning models can aid in detection of PH-COPD, but it is unclear how model features compare to …

us (code pays fourni par la source)

Profiles of patients with pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD)

Hilary M. DuBrock, Kathryn Del Valle, Hannah Barman, Katherine Carlson et autres

Pulmonary hypertension (PH) can be associated with COPD. Low screening rates contribute to poor characterization of these patients. This study compared key clinical characteristics of COPD patients with and without PH. Between 2015-2019 at Mayo Clinic, 3118 PH-COPD patients were identified in …

us (code pays fourni par la source)

Machine learning to detect pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD)

Hilary M. DuBrock, Kathryn Del Valle, Hannah Barman, Katherine B Carlson et autres

Background: PH is a key prognostic indicator in patients with COPD but can be difficult to diagnose due to non-specific symptoms. Right heart catheterization (RHC) is the gold standard diagnostic test for PH; however, it is invasive and not always performed for …

us (code pays fourni par la source)

Prevalence of “HER2 ultra-low” among patients with advanced breast cancer with historical IHC0 status.

Sandhya Mehta, Anushree Iyengar, Hannah Barman, Nivedita Rangarajan et autres

e13156 Background: Breast Cancer (BC) patients are classified as HER2-positive (IHC3+ or IHC2+/ISH+) or HER2-negative (IHC0, IHC1+ and 2+/ISH-). Within the HER2-negative category, patients who meet HER2-low (IHC1+ or IHC2+/ISH-) criteria can benefit from HER2 targeted therapy like trastuzumab deruxtecan. Patients who …

us (code pays fourni par la source)

Evaluation of Clinical Remission Indicators in Asthma Patients Treated With Biologics in a Real-world Setting

Kaiser G. Lim, Thomas C. Corbridge, L. Lee, Hannah Barman et autres

us (code pays fourni par la source)

Identification and Characterization of Immune Checkpoint Inhibitor–Induced Toxicities From Electronic Health Records Using Natural Language Processing

Hannah Barman, Sriram Venkateswaran, Antonio Santo, Unice Yoo et autres

PURPOSE: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, yet their use is associated with immune-related adverse events (irAEs). Estimating the prevalence and patient impact of these irAEs in the real-world data setting is critical for characterizing the benefit/risk profile of ICI …

us, ch (code pays fourni par la source)